PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmccancBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Cancer
 
BMC Cancer. 2007; 7: 83.
Published online 2007 May 15. doi:  10.1186/1471-2407-7-83
PMCID: PMC1887536

BRIP1 (BACH1) variants and familial breast cancer risk: a case-control study

Abstract

Background

Inactivating and truncating mutations of the nuclear BRCA1-interacting protein 1 (BRIP1) have been shown to be the major cause of Fanconi anaemia and, due to subsequent alterations of BRCA1 function, predispose to breast cancer (BC).

Methods

We investigated the effect of BRIP1 -64G>A and Pro919Ser on familial BC risk by means of TaqMan allelic discrimination, analysing BRCA1/BRCA2 mutation-negative index patients of 571 German BC families and 712 control individuals.

Results

No significant differences in genotype frequencies between BC cases and controls for BRIP1 -64G>A and Pro919Ser were observed.

Conclusion

We found no effect of the putatively functional BRIP1 variants -64G>A and Pro919Ser on the risk of familial BC.

Background

Germline mutations in the high-penetrance genes BRCA1 and BRCA2 account for up to 25% of the hereditary forms of breast cancer (BC) [1,2]. The nuclear BRCA1-interacting protein 1 (BRIP1; also referred to as BRCA1-associated C-terminal helicase, BACH1) directly binds the BRCT-motif containing domain of BRCA1, thus likely contributing to its DNA repair and tumour suppressor functions [3,4]. BRIP1 deficiency has been described as the causation for cancer-predisposing Fanconi anaemia [5,6], and a recent study has identified constitutional truncating BRIP1 mutations to confer susceptibility to BC [7].

Several genotyping studies have addressed the association between BRIP1 variants and BC risk, but the results have remained controversial [8-11]. The non-conservative BRIP1 Pro919Ser substitition has been previously reported to be associated with an increased BC risk up to age 50 [12]. We evaluated the effects of BRIP -64G>A, which may affect gene regulation, and Pro919Ser, on a large German familial BC study cohort.

Methods

Study population

The familial breast cancer cohort comprised 571 unrelated German, female index cases (19 to 87 years of age; median 45) without deleterious BRCA1 and BRCA2 mutations. They were collected during the years 1996–2005 through the Institute of Human Genetics (Heidelberg, Germany), the Department of Gynaecology and Obstetrics (Cologne, Germany) and the Department of Medical Genetics (Munich, Germany). According to the German Consortium for Hereditary Breast and Ovarian Cancer, breast cancer cases are classified into six categories based on family history: (A1) families with two or more breast cancer cases including at least two cases with onset below the age of 50 years; (A2) families with at least one male breast cancer case; (B) families with at least one breast cancer and one ovarian cancer case; (C) families with at least two breast cancer cases including one case diagnosed before the age of 50 years; (D) families with at least two breast cancer cases diagnosed after the age of 50 years; (E) single cases of breast cancer with age of diagnosis before 35 years [2]. All women gave written consent to the molecular analysis of the BRCA1 and BRCA2 genes and potential new breast cancer susceptibility genes. Prior to DNA extraction, their blood (EDTA) was frozen at -20°C. The DNA was isolated by a conventional phenol-chloroform protocol. Mutations in the open reading frame of BRCA1 and BRCA2 were excluded by applying denaturing high performance liquid chromatography (DHPLC) on all exons, followed by direct sequencing of conspicuous exons. The control series consisted of 712 healthy, unrelated female blood donors (26 to 68 years of age, median 49). They were recruited in 2004 and 2005 by the Institute of Transfusion Medicine and Immunology (Mannheim, Germany) and share the ethnic background with the breast cancer patients. According to the German guidelines for blood donation, all blood donors were examined by a standard questionnaire. Buffy coat samples were taken from the anti-coagulated blood donations and were used for DNA isolation (FlexiGene® DNA Kit; Qiagen, Hilden Germany). All blood donors consented to the use of their samples for research studies. The study was approved by the Ethics Committee of the University of Heidelberg (Heidelberg, Germany).

Genotyping

BRIP1 genotyping was done by the TaqMan allelic discrimination method as previously described [13]. TaqMan primers and probes were provided by the assay-by-design service (Applied Biosystems, Foster City, CA) and designed on the basis of the GenBank NT_010783 sequence. Sequences of primers and probes are available upon request.

Statistical analysis

Genotype-specific odds ratios (ORs), 95% confidence intervals (95% CIs) and P values were computed by unconditional logistic regression using the Statistical Analysis System software (Version 9.1.; SAS Institute Inc., Cary, NC). Haplotypes were inferred using the SNPHAP programme created by D. Clayton [14]. Power calculation was carried out with the power and sample size calculation software PS version 2.1.31 [15].

Transcription factor search

The search for putative transcription factors was performed using TESS (Transcription Element Search Software, [16]) and TFSEARCH (Searching Transcription Factor Binding Sites, [17]).

Results and discussion

Mutations in the DNA helicase BRIP1 have been implicated in the aetiology of Fanconi anaemia, a genetic disorder that is characterised by congenital abnormalities, progressive bone marrow failure, genomic instability and predisposition to cancer [5-7]. Our study assessed the relevance of the BRIP1 variants -64G>A and Pro919Ser to familial BC. According to transcription factor binding site searches, the replacement of G by A at position -64 leads to the formation of a GATA or CCAAT motif, suggesting an modification of gene expression. BRIP Pro919Ser is located in the BRCA1-interacting domain and may alter protein structure and function.

Genotype frequencies for the analysed polymorphisms were in agreement with Hardy-Weinberg expectations in controls. No significant differences in genotype frequencies between BC cases and controls for either BRIP1 -64G>A or Pro919Ser were observed (see Table Table1).1). Adjustment for age made no significant difference to the results, hence only unadjusted ORs are presented. Our findings are in accord with previously published data [8,11]. Though a recent kin-cohort study has shown a strong association with 4.5- to 6.9-fold familial BC risk for Pro919Ser in premenopausal women [12], our data do not support the observed effect when stratified according to age at diagnosis (see Table Table1).1). Haplotype analysis with BRIP1 -64G>A and Pro919Ser did not indicate any association with familial BC risk (data not shown).

Table 1
Genotype distributions of the BRIP1 variants -64G>A (rs2048718§) and Pro919Ser (rs4986764§) among unrelated German BRCA1/2 mutation-negative familial breast cancer patients and healthy, unrelated female control subjects

The strengths of the present study are represented by a sound sample size and a homogeneous study cohort of a single ethnic group, comprising women selected for familial BC. Only BRCA1 and BRCA2 mutation-negative familial BC cases were considered in order to avoid effects caused by these high-penetrance susceptibility genes. With the present sample size, we had a power of 80% at a significance level of 0.05 to detect an OR of ≥ 1.44 for both -64G>A and Pro919Ser. Moreover, the power of an association study based on cases with a family history of the disease is at least twice higher compared to a study using unselected cases [18]. As data of well-known risk factors (age of menarche, history of pregnancy etc.) were not available, we ignored to test for gene-environment interaction.

Conclusion

Both the BRIP1 -64G>A and Pro919Ser variants show no effect on familial BC risk in the German population.

Abbreviations

BC – breast cancer

BACH1 – BRCA1-associated C-terminal helicase

BRIP1 – BRCA1-interacting protein 1

DHPLC – denaturing high performance liquid chromatography

95% C.I. – 95% confidence interval

OR – odds ratio

SNP – single nucleotide polymorphism

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

BF conducted the experiments, performed data acquisition and interpretation, and drafted the manuscript. KH participated in the study coordination and revised the manuscript. AM, BW, CS, MK, PB, RKS and CRB collected DNA samples and were responsible for the BRCA1/BRCA2 mutation screening. BB designed and coordinated the study and reviewed the manuscript. All authors read and approved the final version of the submitted manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/7/83/prepub

Acknowledgements

The German breast cancer samples were collected within a project funded by the Deutsche Krebshilfe. It was supported by the Center of Molecular Medicine Cologne (CMMC), and the EU, LSHC-CT-2004-503465.

References

  • Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108:171–182. doi: 10.1016/S0092-8674(02)00615-3. [PubMed] [Cross Ref]
  • Meindl A, the German Consortium for Hereditary Breast and Ovarian Cancer Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer. 2002;97:472–480. doi: 10.1002/ijc.1626. [PubMed] [Cross Ref]
  • Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DM. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001;105:149–160. doi: 10.1016/S0092-8674(01)00304-X. [PubMed] [Cross Ref]
  • Cantor S, Drapkin R, Zhang F, Lin Y, Han J, Pamidi S, Livingston DM. The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations. Proc Natl Acad Sci USA. 2004;101:2357–2362. doi: 10.1073/pnas.0308717101. [PubMed] [Cross Ref]
  • Levran O, Attwooll C, Henry RT, Milton KL, Neveling K, Rio P, Batish SD, Kalb R, Velleuer E, Barral S, Ott J, Petrini J, Schindler D, Hanenberg H, Auerbach AD. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia. Nat Genet. 2005;37:931–933. doi: 10.1038/ng1624. [PubMed] [Cross Ref]
  • Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25:5875–5884. doi: 10.1038/sj.onc.1209878. [PubMed] [Cross Ref]
  • Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D, Breast Cancer Susceptibility Collaboration (UK) Easton DF, Stratton MR, Rahman N. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006;38:1239–1241. doi: 10.1038/ng1902. [PubMed] [Cross Ref]
  • Vahteristo P, Yliannala K, Tamminen A, Eerola H, Blomqvist C, Nevanlinna H. BACH1 Ser919Pro variant and breast cancer risk. BMC Cancer. 2006;6:19. doi: 10.1186/1471-2407-6-19. [PMC free article] [PubMed] [Cross Ref]
  • Lewis AG, Flanagan J, Marsh A, Pupo GM, Mann G, Spurdle AB, Lindeman GJ, Visvader JE, Brown MA, Chenevix-Trench G, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer Mutation analysis of FANCD2, BRIP1/BACH1, LMO4 and SFN in familial breast cancer. Breast Cancer Res. 2005;7:R1005–1016. doi: 10.1186/bcr1336. [PMC free article] [PubMed] [Cross Ref]
  • Karppinen SM, Vuosku J, Heikkinen K, Allinen M, Winqvist R. No evidence of involvement of germline BACH1 mutations in Finnish breast and ovarian cancer families. Eur J Cancer. 2003;39:366–371. doi: 10.1016/S0959-8049(02)00498-7. [PubMed] [Cross Ref]
  • Rutter JL, Smith AM, Davila MR, Sigurdson AJ, Giusti RM, Pineda MA, Doody MM, Tucker MA, Greene MH, Zhang J, Struewing JP. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals. Hum Mutat. 2003;22:121–128. doi: 10.1002/humu.10238. [PubMed] [Cross Ref]
  • Sigurdson AJ, Hauptmann M, Chatterjee N, Alexander BH, Doody MM, Rutter JL, Struewing JP. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. BMC Cancer. 2004;4:9. doi: 10.1186/1471-2407-4-9. [PMC free article] [PubMed] [Cross Ref]
  • Frank B, Hemminki K, Wirtenberger M, Bermejo JL, Bugert P, Klaes R, Schmutzler RK, Wappenschmidt B, Bartram CR, Burwinkel B. The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. Carcinogenesis. 2005;26:643–647. doi: 10.1093/carcin/bgh342. [PubMed] [Cross Ref]
  • David Clayton http://www-gene.cimr.cam.ac.uk/clayton/
  • PowerSampleSize http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize
  • TESS : Transcription Element Search System http://www.cbil.upenn.edu/tess
  • TFSEARCH http://www.cbrc.jp/research/db/TFSEARCH.html
  • Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: Implications for design of association studies. Genet Epidemiol. 2003;25:190–202. doi: 10.1002/gepi.10261. [PubMed] [Cross Ref]

Articles from BMC Cancer are provided here courtesy of BioMed Central